{
    "id": "0d1f10eb-de2e-49c3-bbea-2cafbafe05b1",
    "indications": {
        "text": "cyclophosphamide alkylating indicated treatment : \u2022 malignant diseases : malignant lymphomas : hodgkin \u2019 disease , lymphocytic lymphoma , mixed-cell type lymphoma , histiocytic lymphoma , burkitt \u2019 lymphoma ; multiple myeloma , leukemias , mycosis fungoides , neuroblastoma , adenocarcinoma ovary , retinoblastoma , breast carcinoma ( 1.1 ) \u2022 minimal change nephrotic syndrome pediatric patients : biopsy proven minimal change nephrotic syndrome patients failed adequately respond unable tolerate adrenocorticosteroid therapy ( 1.2 ) limitations : safety effectiveness treatment nephrotic syndrome adults renal disease established .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "histiocytic lymphoma (DOID:8538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8538"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "mycosis (DOID:1564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1564"
            },
            {
                "text": "mycosis fungoides (DOID:8691)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8691"
            },
            {
                "text": "neuroblastoma (DOID:769)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_769"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "retinoblastoma (DOID:768)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_768"
            },
            {
                "text": "breast carcinoma (DOID:3459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3459"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "immediately , adequate amounts fluid ingested infused force diuresis order reduce risk urinary tract toxicity . therefore , cyclophosphamide administered morning .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cyclophosphamide injection , usp sterile white powder containing cyclophosphamide supplied vials single dose . cyclophosphamide injection , usp ndc 10019-935-01 500 mg vial , carton 1 ndc 10019-936-01 1 g vial , carton 1 ndc 10019-937-01 2 g vial , carton 1 store vials 25\u00b0c ( 77\u00b0f ) . transport storage cyclophosphamide vials , temperature influences lead melting active ingredient , cyclophosphamide . [ ( 2.3 ) ] . cyclophosphamide antineoplastic product . follow special handling disposal procedures.1",
    "adverseReactions": "\u2022hypersensitivity cyclophosphamide contraindicated patients history severe hypersensitivity , metabolites , components product . anaphylactic including death reported cyclophosphamide . possible cross-sensitivity alkylating agents occur . \u2022urinary outflow obstruction cyclophosphamide contraindicated patients urinary outflow obstruction [ ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "code": "8N3DW7272P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ],
    "organization": "Baxter Healthcare Corporation",
    "name": "CYCLOPHOSPHAMIDE",
    "effectiveTime": "20170315",
    "indications_original": "Cyclophosphamide is an alkylating drug indicated for treatment of: \u2022 Malignant Diseases : malignant lymphomas: Hodgkin\u2019s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt\u2019s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) \u2022 Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established.",
    "contraindications_original": "During or immediately after the administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide should be administered in the morning.",
    "warningsAndPrecautions_original": "Cyclophosphamide for Injection, USP is a sterile white powder containing cyclophosphamide and is supplied in vials for single dose use.\n                  Cyclophosphamide for Injection, USP\n                  \n                     \n                        \u00a0NDC 10019-935-01\t500 mg vial, carton of 1\n                     \n                        \u00a0NDC 10019-936-01\t1 g vial, carton of 1\n                     \n                        \u00a0NDC 10019-937-01\t2 g vial, carton of 1\n                  \n                  Store vials at or below 25\u00b0C (77\u00b0F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide. [see Dosage and Administration (2.3)]. \n                  Cyclophosphamide is an antineoplastic product.  Follow special handling and disposal procedures.1",
    "adverseReactions_original": "\u2022Hypersensitivity\n                     \n                        \u00a0Cyclophosphamide is contraindicated in patients who have a history of severe hypersensitivity reactions to it, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur.\n                     \n                        \u2022Urinary Outflow Obstruction\n                     \n                        \u00a0Cyclophosphamide is contraindicated in patients with urinary outflow obstruction [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ]
}